MINNEAPOLIS, June 13, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell 3000® Index and the Russell Global® Index posted by Russell Investments on June 10, 2011 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 24, 2011.
"The preliminary addition of Uroplasty to the Russell 3000 and Russell Global indexes is a testament to the progress we have made in building valuation," said David Kaysen, president and CEO of Uroplasty. "It should help expand awareness of our company, especially among institutional investors, as we continue to execute our growth strategy for our Urgent PC® and Macroplastique® product lines."
The Russell 3000 Index measures the performance of the largest 3000 U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell Global Index measures the performance of the global equity market based on all investable equity securities, and includes approximately 10,000 securities in 48 countries and covers 98% of the investable global market. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The indexes are reconstituted annually.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, Treasurer
Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820
Chris Gale (Media), 646.201.5431
|SOURCE Uroplasty, Inc.|
Copyright©2010 PR Newswire.
All rights reserved